

GZMH Antibody (N-term) Blocking Peptide Synthetic peptide

Catalog # BP6576a

Specification

GZMH Antibody (N-term) Blocking Peptide - Product Information

Primary Accession

<u>P20718</u>

GZMH Antibody (N-term) Blocking Peptide - Additional Information

Gene ID 2999

Other Names Granzyme H, 3421-, CCP-X, Cathepsin G-like 2, CTSGL2, Cytotoxic T-lymphocyte proteinase, Cytotoxic serine protease C, CSP-C, GZMH, CGL2, CTSGL2

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP6576a was selected from the N-term region of human GZMH. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures.

GZMH Antibody (N-term) Blocking Peptide - Protein Information

Name GZMH

Synonyms CGL2, CTSGL2

Function

Cytotoxic chymotrypsin-like serine protease with preference for bulky and aromatic residues at the P1 position and acidic residues at the P3' and P4' sites. Probably necessary for target cell lysis in cell-mediated immune responses. Participates in the antiviral response via direct cleavage of several proteins essential for viral replication.

Cellular Location Cytolytic granule.

Tissue Location



Constitutively expressed in NK cells.

GZMH Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

<u>Blocking Peptides</u>

GZMH Antibody (N-term) Blocking Peptide - Images

GZMH Antibody (N-term) Blocking Peptide - Background

GZMH is probably necessary for target cell lysis in cell-mediated immune responses.

GZMH Antibody (N-term) Blocking Peptide - References

Romero,V., Cell Death Differ. 16 (2), 340-348 (2009)Hou,Q., Mol. Immunol. 45 (4), 1044-1055 (2008)Waterhouse,N.J., Trends Immunol. 28 (9), 373-375 (2007)